文献速递神经肿瘤

WHO 4级星形细胞瘤交替电场治疗后的健康相关生活质量:前瞻性真实世界多中心研究

Health-related quality-of-life of WHO grade 4 astrocytoma patients receiving alternating electrical field therapy: a prospective real-world multi-centre study.
PubMed 文献 · J Neurooncol · 2026-05-21

该前瞻性多中心注册研究纳入88例WHO 4级星形细胞瘤成人患者,比较交替电场(AEF)联合放化疗与单纯放化疗。结果显示,治疗后3个月AEF联合组全球生活质量评分显著低于单纯放化疗组,功能与症状评分及照护者压力总体稳定。

要点

  • AEF联合放化疗组3个月全球生活质量评分显著低于单纯放化疗组。
  • AEF治疗与术前KPS≥80均与高全球生活质量几率降低独立相关。
  • 除头皮瘙痒外,两组功能与症状评分及照护者压力无显著差异。

核心结论

  • 在WHO 4级星形细胞瘤中国患者中,AEF治疗与3个月全球健康相关生活质量降低独立相关。
  • 功能与症状领域及照护者压力在两组间总体保持稳定。

研究设计与样本

  • 前瞻性、多中心、基于注册的研究,纳入88例接受AEF联合放化疗(48例)或单纯放化疗(40例)的成人WHO 4级星形细胞瘤患者。
  • 使用EORTC QLQ-C30/BN20、CSI和HK-MoCA在基线和每3个月评估,主要终点为放化疗后3个月全球QLQ-30评分。

主要发现

  • 3个月时AEF联合组全球QLQ-C30评分显著低于单纯放化疗组(44±22 vs. 66±20;组间差异22分;p<0.001),超过胶质瘤最小重要差异4-6分。
  • 多因素分析显示,AEF治疗(校正OR 0.09,95%CI 0.006-0.7)和术前KPS≥80(校正OR 0.09,95%CI 0.01-0.5)与高全球生活质量(≥60)几率降低相关。
  • 除AEF联合组头皮瘙痒更常见外,两组功能与症状评分相当。
  • 照护者CSI平均评分在所有时间点均<7。

临床怎么用

  • 在权衡AEF生存获益与短期生活质量负担时,应参考本数据开展共享决策。
  • 在亚热带气候地区,需关注AEF相关头皮不良反应对生活质量的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Alternating electric fields (AEF) therapy has been shown to improve the overall survival of patients with WHO grade 4 astrocytoma. Few have explored its impact on health-related quality-of-life (HRQoL) and caregiver stress. METHODS: This was a prospective, multi-centre, registry-based study of adult patients with WHO grade 4 astrocytoma who received either AEF plus temozolomide chemoradiotherapy (AEF + CRT) or CRT alone, with EORTC QLQ-C30/BN20, CSI, and HK-MoCA assessments at baseline and every three months. The primary outcome was the global QLQ-30 score at 3 months after CRT. Secondary outcomes included the QLQ-30 functional score, symptom scores and the caregiver stress index (CSI) at 3 months. RESULTS: 88 patients, 48 AEF + CRT and 40 CRT-alone, were reviewed. The mean AEF duration was 10 ± 8 months. At 3 months, AEF + CRT patients had significantly lower global QLQ-C30 scores than CRT-alone patients (44 ± 22 vs. 66 ± 20; between-group difference 22 points; p < 0.001), exceeding the established minimally important difference of 4-6 points for glioma. On multivariable analysis, AEF therapy (adjusted OR 0.09, 95% CI 0.006-0.7) and preoperative KPS ≥ 80 (adjusted OR 0.09, 95% CI 0.01-0.5) were associated with lower odds of high global QoL (≥ 60). Functional and symptom scores were comparable between groups, apart from higher scalp pruritus in AEF + CRT patients. Mean caregiver CSI scores remained < 7 at all time points. CONCLUSION: In this prospective real-world cohort of Chinese patients with WHO grade 4 astrocytoma, AEF therapy was independently associated with a reduction in global HRQoL at 3 months compared with CRT alone, while functional and symptom domains and caregiver stress remained largely stable. These data should inform shared decision-making when weighing the survival benefit of AEF against its short-term QoL burden, especially in subtropical climates where scalp-related adverse effects may be more pronounced.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wong DKK, Pu JKS, Li LF, et al. Health-related quality-of-life of WHO grade 4 astrocytoma patients receiving alternating electrical field therapy: a prospective real-world multi-centre study. J Neurooncol. 2026. PMID: 42168436. doi:10.1007/s11060-026-05631-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。